Inventor · disambiguated record
Michael D. Wendt
Also filed as: WENDT MICHAEL · WENDT MICHAEL D
48 granted patents·45 pending applications·1,330 citations·filing 1995–2024
99Inventor score
Top patents by PatentIndex Score
93 records- 0198US8546399B2Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesBRUNCKO MILAN·Filed 2010·Granted Oct 1, 2013·100 cites·24 claims
- 0298US7973161B2Apoptosis promotersABBOTT LAB·Filed 2006·Granted Jul 5, 2011·70 cites·5 claims
- 0398US7767684B2Apoptosis promotersABBOTT LAB·Filed 2005·Granted Aug 3, 2010·107 cites·7 claims
- 0498US7642260B2Apoptosis promotersABBOTT LAB·Filed 2005·Granted Jan 5, 2010·82 cites·2 claims
- 0598US6720338B2N-acylsulfonamide apoptosis promotersABBOTT LAB·Filed 2001·Granted Apr 13, 2004·98 cites·9 claims
- 0697US9174982B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted Nov 3, 2015·38 cites·7 claims
- 0797US8686136B2Apoptosis promotersABBVIE INC·Filed 2012·Granted Apr 1, 2014·20 cites·2 claims
- 0897US8586754B2BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesBRUNCKO MILAN·Filed 2010·Granted Nov 19, 2013·59 cites·8 claims
- 0997US8563735B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesBRUNCKO MILAN·Filed 2009·Granted Oct 22, 2013·72 cites·4 claims
- 1097US8354404B2Apoptosis promotersABBOTT LAB·Filed 2011·Granted Jan 15, 2013·39 cites·8 claims
- 1197US8173811B2Apoptosis promotersBRUNCKO MILAN·Filed 2010·Granted May 8, 2012·50 cites·4 claims
- 1297US7754886B2N-acylsulfonamide apoptosis promotersABBOTT LAB·Filed 2009·Granted Jul 13, 2010·34 cites·18 claims
- 1397US7504512B2N-acylsulfonamide apoptosis promotersABBOTT LAB·Filed 2004·Granted Mar 17, 2009·58 cites·18 claims
- 1496US8614318B2Apoptosis promotersBRUNCKO MILAN·Filed 2006·Granted Dec 24, 2013·37 cites·2 claims
- 1596US8084607B2Apoptosis promotersBRUNCKO MILAN·Filed 2009·Granted Dec 27, 2011·43 cites·5 claims
- 1695US9045444B2Apoptosis promotersABBVIE INC·Filed 2014·Granted Jun 2, 2015·11 cites·3 claims
- 1795US8343967B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBOTT LAB·Filed 2012·Granted Jan 1, 2013·32 cites·2 claims
- 1894US9315488B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2015·Granted Apr 19, 2016·13 cites·2 claims
- 1994US9073855B2BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Jul 7, 2015·11 cites·2 claims
- 2094US9045420B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Jun 2, 2015·11 cites·1 claims
- 2194US8952157B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted Feb 10, 2015·22 cites·5 claims
- 2294US8426422B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesHEXAMER LAURA A·Filed 2010·Granted Apr 23, 2013·49 cites·4 claims
- 2394US6258822B1Urokinase inhibitorsABBOTT LAB·Filed 1998·Granted Jul 10, 2001·70 cites·5 claims
- 2492US8940737B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2012·Granted Jan 27, 2015·7 cites·10 claims
- 2591US9303025B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Apr 5, 2016·11 cites·4 claims
- 2691US8338466B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesKUNZER AARON R·Filed 2010·Granted Dec 25, 2012·15 cites·6 claims
- 2790US9072748B2BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Jul 7, 2015·11 cites·10 claims
- 2889US10676485B2Macrocyclic MCL-1 inhibitors and methods of useABBVIE INC·Filed 2018·Granted Jun 9, 2020·2 cites·2 claims
- 2989US9125913B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Sep 8, 2015·10 cites·6 claims
- 3089US7910742B2Survivin inhibitorsABBOTT LAB·Filed 2006·Granted Mar 22, 2011·9 cites·1 claims
- 3188US8889675B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2012·Granted Nov 18, 2014·3 cites·9 claims
- 3287US6046207ABenzopyranopyrrole and benzopyranopyridine α-1 adrenergic compoundsFiled 1997·Granted Apr 4, 2000·37 cites·4 claims
- 3387US2024285611A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2023·Application pending·0 cites
- 3486US9266877B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Feb 23, 2016·2 cites·2 claims
- 3586US9227963B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Jan 5, 2016·2 cites·2 claims
- 3686US2025313572A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2024·Application pending·0 cites
- 3786US2025019364A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2024·Application pending·0 cites
- 3884US8188077B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesDING HONG·Filed 2011·Granted May 29, 2012·8 cites·5 claims
- 3984US5891882ABenzopyranopyrrole and benzopyranopyridine α-1 adenergic compoundsABBOTT LAB·Filed 1997·Granted Apr 6, 1999·29 cites·33 claims
- 4084US2025177374A1BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the SameABBVIE INC·Filed 2024·Application pending·0 cites
- 4183US2024043404A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2023·Application pending·0 cites
- 4282US11897864B2Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2022·Granted Feb 13, 2024·0 cites·27 claims
- 4382US2024228509A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2023·Application pending·0 cites
- 4481US2025092062A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2024·Application pending·0 cites
- 4578US2023399340A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2022·Application pending·0 cites
- 4677US9877958B2Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2016·Granted Jan 30, 2018·1 cites·16 claims
- 4777US9844547B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2015·Granted Dec 19, 2017·1 cites·10 claims
- 4877US9561231B2Pyridinone and pyridazinone derivativesABBVIE INC·Filed 2013·Granted Feb 7, 2017·4 cites·43 claims
- 4977US2024058450A1BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the SameABBVIE INC·Filed 2022·Application pending·0 cites
- 5077US2022259226A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 93 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →